Clinical Trials on Antibodies Drug Specific in New Zealand

Total 510 results

Eli Lilly and Company
Locemia Solutions ULC

Completed

Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia

Diabetes Mellitus | Hypoglycemia | Drug-Specific Antibodies

United States, Canada
Proacta, Incorporated

Completed

A Phase I Dose Escalation Trial of PR104 Given Weekly in Subjects With Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

New Zealand
University of Otago
oVRcome

Active, not recruiting

oVRcome Self-guided Virtual Reality for Specific Phobias (oVRcome)

Specific Phobia

New Zealand
Proacta, Incorporated

Completed

PR-104 and Docetaxel or Gemcitabine in Treating Patients With Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

New Zealand, United States
Proacta, Incorporated

Completed

PR104 and G-CSF in Treating Patients With Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States, New Zealand
NYU Langone Health
National Cancer Institute (NCI)

Completed

Chemotherapy and Amifostine in Treating Patients With Recurrent or Refractory Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific | Drug/Agent Toxicity by Tissue/Organ

United States
Databean
Octapharma

Terminated

A Prospective, Global, Multi-center, Treatment Registry Study of Intravenous Immunoglobulin Maintenance Therapy in Alloantibody Positive Renal Allograft Recipients (DSA)

Renal Transplant Recipients With Anti-HLA Antibodies

United States
Albert Einstein College of Medicine

Completed

Studies of Sulfur Metabolism in Humans

Metabolic Side Effects of Drugs

United States
Proacta, Incorporated

Terminated

A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

New Zealand, United States
Sumitomo Pharma America, Inc.

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Drug Interaction Potential of Napabucasin in Healthy Volunteers

Drug-drug Interactions

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI); Rutgers Cancer Institute of New Jersey

Withdrawn

Molecular Markers and Genetic Markers in Patients Undergoing Radiation Therapy for Cancer

Unspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol Specific | Hematopoietic/Lymphoid Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Arsenic Trioxide in Treating Patients With Advanced Solid Tumors

Unspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol Specific

United States
NYU Langone Health
New York City Health and Hospitals Corporation

Completed

Feasibility of Telephone Follow-up Visits in Primary Care

No Specific Condition

United States
University of Medicine and Dentistry of New Jersey
National Cancer Institute (NCI)

Terminated

Dextromethorphan in Treating Patients With Fatigue Caused by Cancer

Unspecified Childhood Solid Tumor, Protocol Specific | Fatigue | Unspecified Adult Solid Tumor, Protocol Specific

United States
National Institute of Allergy and Infectious Diseases...
Clinical Trials in Organ Transplantation; Cooperative Clinical Trials in Pediatric...

Completed

Rituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies

Kidney Transplant | Kidney Transplant Recipient | Graft Function/Survival | de Novo HLA Antibodies Development

United States
Daiichi Sankyo, Inc.

Completed

Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)

Drug Interaction Potential

United States, New Zealand, Taiwan, Netherlands
Daiichi Pharmaceuticals

Withdrawn

Soblidotin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

ILX23-7553 in Treating Patients With Solid Tumors That Have Not Responded to Previous Therapy

Unspecified Adult Solid Tumor, Protocol Specific

United States
NYU Langone Health
National Cancer Institute (NCI)

Completed

R115777 Plus Topotecan in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Ifosfamide and Topotecan in Treating Patients With Refractory Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

Paclitaxel Plus Topotecan in Treating Patients With Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
NYU Langone Health
National Cancer Institute (NCI)

Completed

Bryostatin 1 Plus Cisplatin in Treating Patients With Metastatic or Unresectable Cancer

Unspecified Adult Solid Tumor, Protocol Specific

United States
Roswell Park Cancer Institute
Abbott

Completed

Paricalcitol and Gemcitabine in Treating Patients With Advanced Cancer

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Terminated

Oxaliplatin and Bortezomib in Treating Patients With Advanced Cancer

Unspecified Adult Solid Tumor, Protocol Specific

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

T138067 Sodium in Treating Patients With Advanced Refractory Cancer

Unspecified Adult Solid Tumor, Protocol Specific

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Polyglutamate Camptothecin in Treating Patients With Advanced Cancer

Unspecified Adult Solid Tumor, Protocol Specific

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

BMS-214662 in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Cisplatin and Everolimus in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Irinotecan in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

Alvocidib, Oxaliplatin, Fluorouracil, and Leucovorin Calcium in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

SJG-136 in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Fluorouracil Plus UCN-01 in Treating Patients With Advanced or Refractory Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Flavopiridol and Irinotecan in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Montefiore Medical Center
National Cancer Institute (NCI)

Completed

Ixabepilone and Ketoconazole in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Montclair State University
National Cancer Institute (NCI)

Unknown

Promoting Physical Activity In After-School Programs for Urban Adolescents

Unspecified Adult Solid Tumor, Protocol Specific

United States
Roswell Park Cancer Institute

Completed

Calcitriol, Ketoconazole, and Dexamethasone in Treating Patients With Metastatic or Unresectable Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Roswell Park Cancer Institute
Cleveland BioLabs, Inc.

Completed

Entolimod in Treating Patients With Locally Advanced or Metastatic Solid Tumors That Cannot Be Removed By Surgery

Unspecified Adult Solid Tumor, Protocol Specific

United States
Yale University
National Cancer Institute (NCI)

Completed

Topotecan Plus Sargramostim in Treating Patients With Advanced Cancer

Unspecified Adult Solid Tumor, Protocol Specific

United States
Yale University
National Cancer Institute (NCI)

Terminated

High-Dose Topotecan and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer

Unspecified Adult Solid Tumor, Protocol Specific

United States
Vion Pharmaceuticals

Completed

3-AP in Treating Patients With Advanced Cancer

Unspecified Adult Solid Tumor, Protocol Specific

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Huang Lian (Chinese Herb) in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Ro 31-7453 in Treating Patients With Locally Advanced or Metastatic Solid Tumor

Unspecified Adult Solid Tumor, Protocol Specific

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Ro 31-7453 in Treating Patients With Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Safingol and Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Gefitinib and Docetaxel in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

BMS-247550 and Gemcitabine in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Completed

Docetaxel, Capecitabine, and Cisplatin in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Dartmouth-Hitchcock Medical Center
National Cancer Institute (NCI)

Completed

Temozolomide Plus PEG-Interferon Alfa-2B in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Roswell Park Cancer Institute

Completed

Calcitriol and Gefitinib With or Without Dexamethasone in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States

Clinical Trials on Antibodies Drug Specific in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mozambique

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations